Literature DB >> 28173728

Metabolic changes in normal-appearing white matter in patients with neuromyelitis optica and multiple sclerosis: a comparative magnetic resonance spectroscopy study.

Yunyun Duan1,2, Zheng Liu3, Yaou Liu1,2, Jing Huang1,2, Zhuoqiong Ren1,2, Zheng Sun1,2, Hai Chen3, Huiqing Dong3, Jing Ye3, Kuncheng Li1,2.   

Abstract

Background Previous studies with a small sample size have not reported metabolic changes in neuromyelitis optica (NMO). Metabolic changes, such as decreased N-acetylaspartate (NAA), are well-established in patients with multiple sclerosis (MS). It remains unknown whether different patterns of metabolic changes occur in NMO and MS. Purpose To investigate the metabolic changes in normal-appearing white matter (NAWM) in NMO, compared with MS patients and healthy controls (HC), and correlate these changes with clinical disability. Material and Methods We recruited 27 patients with NMO, 24 patients with MS, and 24 HC. Each participant underwent chemical shift imaging with a 1H-MR spectroscopy operating in a 1.5 T magnetic resonance imaging (MRI) scanner. The absolute concentrations of NAA, choline (Cho), creatine (Cr) as well as the metabolite ratios of NAA/Cr, Cho/Cr, and NAA/Cho were measured and compared among the groups. The correlations between the metabolic concentrations, disease duration, and clinical disability (Expanded Disability Status Scale, EDSS) were further explored. Results Compared with HC, a mild increase of Cho without significant NAA changes was observed in NMO patients, while both a significant reduction of NAA and an increase of Cho were observed in MS patients. The absolute concentration of NAA and NAA/Cho ratio were significantly decreased in MS patients in a direct comparison with NMO patients. In MS patients, the EDSS was correlated with the NAA/Cr and Cho/Cr ratios. Conclusion A reduction of NAA was not observed in NMO, implying axonal or neuronal damage may be absent in NAWM for NMO, which is different from MS. A mild increase in Cho was observed in NAWM of NMO patients, suggesting that subtle metabolic changes occur in NMO.

Entities:  

Keywords:  Neuromyelitis optica (NMO); magnetic resonance spectroscopy (MRS); multiple sclerosis (MS); normal appearing white matter (NAWM)

Mesh:

Substances:

Year:  2017        PMID: 28173728     DOI: 10.1177/0284185116683575

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  5 in total

1.  Quantitative 7T MRI does not detect occult brain damage in neuromyelitis optica.

Authors:  Baptiste Pasquier; Nadja Borisow; Ludwig Rasche; Judith Bellmann-Strobl; Klemens Ruprecht; Thoralf Niendorf; Tobias J Derfuss; Jens Wuerfel; Friedemann Paul; Tim Sinnecker
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-03-07

Review 2.  Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker.

Authors:  Kelley M Swanberg; Karl Landheer; David Pitt; Christoph Juchem
Journal:  Front Neurol       Date:  2019-11-15       Impact factor: 4.003

3.  18F-florbetapir PET/MRI for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis: A longitudinal study.

Authors:  Min Zhang; You Ni; Qinming Zhou; Lu He; Huanyu Meng; Yining Gao; Xinyun Huang; Hongping Meng; Peihan Li; Meidi Chen; Danni Wang; Jingyi Hu; Qiu Huang; Yao Li; Fabien Chauveau; Biao Li; Sheng Chen
Journal:  EClinicalMedicine       Date:  2021-06-23

Review 4.  In vivo Human MR Spectroscopy Using a Clinical Scanner: Development, Applications, and Future Prospects.

Authors:  Moyoko Tomiyasu; Masafumi Harada
Journal:  Magn Reson Med Sci       Date:  2022-02-15       Impact factor: 2.760

5.  Changes in mitochondrial function in patients with neuromyelitis optica; correlations with motor and cognitive disabilities.

Authors:  Forough Foolad; Fariba Khodagholi; Seyed Massood Nabavi; Mohammad Javan
Journal:  PLoS One       Date:  2020-03-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.